



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Frontiers Production Office,  
✉ production.office@frontiersin.org

RECEIVED 07 June 2023  
ACCEPTED 07 June 2023  
PUBLISHED 13 June 2023

CITATION  
Frontiers Production Office (2023),  
Erratum: Development of a quaternary  
ammonium poly (amidoamine)  
dendrimer-based drug carrier for the  
solubility enhancement and sustained  
release of furosemide.  
*Front. Chem.* 11:1236207.  
doi: 10.3389/fchem.2023.1236207

COPYRIGHT  
© 2023 Frontiers Production Office. This  
is an open-access article distributed  
under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction in  
other forums is permitted, provided the  
original author(s) and the copyright  
owner(s) are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# Erratum: Development of a quaternary ammonium poly (amidoamine) dendrimer-based drug carrier for the solubility enhancement and sustained release of furosemide

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

PAMAM dendrimer, congestive heart failure, solubility enhancement, sustained release, biocompatibility

## An Erratum on

**Development of a quaternary ammonium poly (amidoamine) dendrimer-based drug carrier for the solubility enhancement and sustained release of furosemide**

by Murugan E and Yogaraj V (2023). *Front. Chem.* 11:1123775. doi: [10.3389/fchem.2023.1123775](https://doi.org/10.3389/fchem.2023.1123775)

Due to an Editorial Office error, the following declaration was missed from the **Conflict of Interest** statement: “The handling editor NJ declared a past collaboration with the author EM.”

The publisher apologizes for this mistake. The original version of this article has been updated.